Literature DB >> 11118104

Orlistat decreases the plasma level of cyclosporine and may be responsible for the development of acute rejection episodes.

B Schnetzler, M Kondo-Oestreicher, D Vala, G Khatchatourian, B Faidutti.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11118104     DOI: 10.1097/00007890-200011270-00025

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


× No keyword cloud information.
  7 in total

1.  Medical management of obesity: present and future therapy.

Authors:  Samuel Klein
Journal:  J Gastrointest Surg       Date:  2003 May-Jun       Impact factor: 3.452

Review 2.  Orlistat-associated adverse effects and drug interactions: a critical review.

Authors:  Theodosios D Filippatos; Christos S Derdemezis; Irene F Gazi; Eleni S Nakou; Dimitri P Mikhailidis; Moses S Elisaf
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

3.  Example of the drug interaction between ciclosporin and orlistat, resulting in relapse of Evan's syndrome.

Authors:  Irina Earnshaw; Jecko Thachil
Journal:  BMJ Case Rep       Date:  2016-10-28

Review 4.  Orlistat: in the prevention and treatment of type 2 diabetes mellitus.

Authors:  G M Keating; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 5.  Obesity and liver transplantation.

Authors:  Subhashini Ayloo; John Armstrong; Scott Hurton; Michele Molinari
Journal:  World J Transplant       Date:  2015-09-24

Review 6.  Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients.

Authors:  Anders Asberg
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 7.  Multidirectional facets of obesity management in the metabolic syndrome population after liver transplantation.

Authors:  Kinga Czarnecka; Paulina Czarnecka; Olga Tronina; Teresa Bączkowska; Magdalena Durlik
Journal:  Immun Inflamm Dis       Date:  2021-10-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.